Cart
sales@molnova.com
HBV-IN-37
CAS No. 380483-01-2
HBV-IN-37( —— )
Catalog No. M37076 CAS No. 380483-01-2
HBV-IN-37 is an HBV inhibitor with an EC50 value of 10 μM and can be used for hepatitis B disease-related research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 42 | In Stock |
|
| 25MG | 70 | In Stock |
|
| 50MG | 102 | In Stock |
|
| 100MG | 152 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHBV-IN-37
-
NoteResearch use only, not for human use.
-
Brief DescriptionHBV-IN-37 is an HBV inhibitor with an EC50 value of 10 μM and can be used for hepatitis B disease-related research.
-
DescriptionHBV-IN-37 is an inhibitor of HBV with an EC50 value of 10 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number380483-01-2
-
Formula Weight439.96
-
Molecular FormulaC23H22ClN3O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(N1C(C=2C(=NN(C2)C3=CC=CC=C3)C4=CC=C(Cl)C=C4)SCC1=O)C5CCCO5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Ibandronate sodium
Ibandronate Sodium is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
-
ccc_R08
ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).
-
GLP-26
GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM.
